Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria.
about
Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malariaArtemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malariaArtemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malariaArtemisinin-based combination therapy for the treatment of uncomplicated Plasmodium vivax malaria and the prevention of relapsesArtemisinin-based combination therapy for treating uncomplicated malariaArtemisinin-based combination therapies: a vital tool in efforts to eliminate malariaArtemisinin combination therapy for vivax malariaThe effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient dataAntimalarial efficacy of piperaquine-based antimalarial combination therapies: facts and uncertaintiesThe anaemia of Plasmodium vivax malariaSelection of drug resistance-mediating Plasmodium falciparum genetic polymorphisms by seasonal malaria chemoprevention in Burkina FasoEpidemiology of Plasmodium vivax in IndonesiaEfficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium vivax malaria in endemic countries: meta-analysis of randomized controlled studiesDihydroartemisinin-piperaquine vs. artemether-lumefantrine for first-line treatment of uncomplicated malaria in African children: a cost-effectiveness analysisCharacterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose-Efficacy ModelingMalaria Distribution, Prevalence, Drug Resistance and Control in IndonesiaVivax malaria: neglected and not benignThe effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient dataSevere congenital malaria acquired in utero.Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria.Amplification of pvmdr1 associated with multidrug-resistant Plasmodium vivaxVivax malaria: a major cause of morbidity in early infancy.In vivo and in vitro efficacy of amodiaquine monotherapy for treatment of infection by chloroquine-resistant Plasmodium vivax.Resistance to therapies for infection by Plasmodium vivaxDihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial.Evaluation of chloroquine therapy for vivax and falciparum malaria in southern Sumatra, western Indonesia.In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax.Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina FasoDihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial.Protective efficacy of malaria case management and intermittent preventive treatment for preventing malaria mortality in children: a systematic review for the Lives Saved ToolPlasmodium falciparum gametocyte carriage is associated with subsequent Plasmodium vivax relapse after treatment.Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trialEpidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and eliminationEfficacy and safety of artemisinin-naphthoquine versus dihydroartemisinin-piperaquine in adult patients with uncomplicated malaria: a multi-centre study in IndonesiaA phase III, randomized, non-inferiority trial to assess the efficacy and safety of dihydroartemisinin-piperaquine in comparison with artesunate-mefloquine in patients with uncomplicated Plasmodium falciparum malaria in southern Laos.Malaria: an update on current chemotherapy.In vitro piperaquine susceptibility is not associated with the Plasmodium falciparum chloroquine resistance transporter geneEfficacy and safety of artemisinin combination therapy (ACT) for non-falciparum malaria: a systematic review.Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics.Gametocyte dynamics and the role of drugs in reducing the transmission potential of Plasmodium vivax
P2860
Q24201077-562DB27B-FDC3-49F4-BECB-9C6399A6CE95Q24202910-E548329A-3898-44C1-A5C5-302B7A719D02Q24235351-4D762CA2-4F5D-4F39-94ED-6B1BC340C7B2Q24236067-971C617F-9EAE-475D-A63E-A88338F07C3FQ24241785-49A053F1-D25E-4707-BDD2-209A033FC869Q24614989-757232A3-60A6-4E27-AB91-539AA9D64E07Q24622539-884FD1B0-6800-4569-ADE2-CE2006CE863FQ26822489-D5C55085-CD0F-4E58-8B5E-FF3B7A51CE8BQ26866187-39C40E23-D5B8-4B24-9F88-09CF66F18876Q27026970-EA2CEB6B-8732-4401-BC51-69E6D65320C9Q28125901-1493E432-848A-4CB3-8917-0DC1ADFA9790Q28355357-B3F45AB3-CEAC-4CD1-A4DC-2D89B12D25FBQ28535686-5112A656-0A5A-47D7-A71A-C4D7F30AB174Q28538065-2AD8EA4A-6446-4165-BDA5-A1C384346D53Q28554466-27F994F5-0548-400A-B8C5-D15D077A5647Q29306432-8B91E537-6787-4360-B4DE-0B50EAF44074Q29619167-FE77314F-0121-4F3F-8909-48D73ADEB874Q30936416-DE7FB896-F2C2-4584-9461-EEE7459A24A4Q30980068-40E1DE2B-46D1-4DC0-9430-16451C9EB454Q33298467-1D07D8A0-7352-43CD-AC62-4B915CE97414Q33371043-4960B6C1-30F9-403D-9BFD-C0A6C01CF4E3Q33384482-07297F05-9744-4EB9-B3F9-50EDB774D742Q33395221-9C44C54A-D611-41BE-8E98-425FC2E8CF3DQ33481576-20AAC64F-625B-4B60-82EF-B2A756D94222Q33516563-43556FC8-6856-46DE-88FC-30B889AD2641Q33530920-D8D89C04-8A2F-4B9C-8DBB-E2189E3207CAQ33704762-EB2EDD49-B277-4EDB-A031-3008F29F1BA2Q33826359-71B93BA3-A362-426D-8474-9B3C2EE21EF9Q33828657-D0990130-1BA6-42F1-8F3B-86A2412278DAQ33875677-1E56E3E7-F12A-46AB-A30E-9352879095A8Q33886228-71431F89-7CDB-4CB1-8110-F36B1A8C8CBFQ34049080-E3D2A7CE-4B8B-4C96-9990-C2C9C3901AC2Q34177472-0D857E39-E94D-447A-B8A9-4437B35AF259Q34254961-1E1C99CD-6A79-42E2-9D24-356A5EFCBD75Q34341784-2F1EDB62-B92E-4D7A-9BB9-7E5E4B4A845EQ34433106-6BD10891-EEA5-4924-8D24-D23123367482Q34478084-DFB25D9C-1D85-4EB0-A4B1-7F40593F14B3Q34646141-BA6440EE-0B49-43CF-9C8C-96E78234845FQ34699136-85030063-5821-4408-8C6B-827B3BFCC73EQ34772862-BF25E173-CC31-4F10-9D24-4E3F8D7CEA86
P2860
Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria.
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Dihydroartemisinin-piperaquine ...... and Plasmodium vivax malaria.
@ast
Dihydroartemisinin-piperaquine ...... and Plasmodium vivax malaria.
@en
type
label
Dihydroartemisinin-piperaquine ...... and Plasmodium vivax malaria.
@ast
Dihydroartemisinin-piperaquine ...... and Plasmodium vivax malaria.
@en
prefLabel
Dihydroartemisinin-piperaquine ...... and Plasmodium vivax malaria.
@ast
Dihydroartemisinin-piperaquine ...... and Plasmodium vivax malaria.
@en
P2093
P2860
P921
P356
P1476
Dihydroartemisinin-piperaquine ...... and Plasmodium vivax malaria.
@en
P2093
A R Hasugian
E Kenangalem
E P Ebsworth
H L E Purba
P M P Penttinen
R M Wuwung
R Maristela
P2860
P304
P356
10.1086/512677
P407
P577
2007-03-05T00:00:00Z